Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 4,185 GBp
Change Today -6.00 / -0.14%
Volume 596.7K
AZN On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 5:21 AM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (AZN) Snapshot

Open
4,209 GBp
Previous Close
4,191 GBp
Day High
4,218 GBp
Day Low
4,177 GBp
52 Week High
04/23/15 - 4,906 GBp
52 Week Low
06/30/15 - 4,019 GBp
Market Cap
52.9B
Average Volume 10 Days
1.9M
EPS TTM
1.02 GBp
Shares Outstanding
1.3B
EX-Date
02/19/15
P/E TM
64.0x
Dividend
3.06 GBp
Dividend Yield
4.70%
Current Stock Chart for ASTRAZENECA PLC (AZN)

astrazeneca plc (AZN) Details

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort Turbuhaler/Pulmicort Flexhaler for treating asthma; Symbicort for maintenance treatment of asthma and chronic obstructive pulmonary disease; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. As of December 31, 2014, it had 133 pipeline projects. The company markets its products through distributors and local representative offices. In addition, it engages in the insurance and reinsurance underwriting business. The company has collaboration agreements with Celgene Corporation, Immunocore Limited, Kyowa Hakko Kirin Co., Ltd., Advaxis Inc., and Pharmacyclics Inc. and Janssen Research & Development, LLC. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

57,500 Employees
Last Reported Date: 03/10/15
Founded in 1992

astrazeneca plc (AZN) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.1M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 1.7M GBP
Compensation as of Fiscal Year 2014.

astrazeneca plc (AZN) Key Developments

Fujifilm Kyowa Kirin Biologics Co. Ltd. Establishes Joint Venture with AstraZeneca plc to Develop and Commercialize Anti-Vegf Biosimilar

Fujifilm Kyowa Kirin Biologics Co. Ltd. announced that it has entered into an agreement with AstraZeneca plc to establish a joint venture for the development and commercialisation of FKB238 in development for the treatment of multiple solid tumours. FKB238 is a biosimilar version of bevacizumab, an anti-VEGF1 humanized monoclonal antibody with established efficacy across a range of cancers including colorectal and non-small cell lung cancer2. Fujifilm Kyowa Kirin Biologics commenced its Phase I clinical trial for FKB238 in Europe in November 2014. Under the terms of the agreement, the new joint venture that is equally co-funded by the two companies and will use FKB238s non-clinical, clinical development data compiled by Fujifilm Kyowa Kirin Biologics thus far. Fujifilm Kyowa Kirin Biologics will transfer the rights to FKB238 to the new joint venture, and will receive a lump-sum payment of USD 45 million in return.

AstraZeneca Commences Phase IIa Trial in Severe Asthma

Synairgen plc announced that AstraZeneca has commenced its Phase IIa study of AZD9412 (inhaled interferon beta, developed by Synairgen and formerly known as SNG001). The study population will comprise patients with severe asthma, building on the clinical data from Synairgen's exploratory Phase lla trial in moderate to severe asthma, which showed that difficult to treat asthma patients appeared to derive most benefit from therapy. AZD9412, a novel, inhaled interferon beta, supports the immune system by correcting a deficiency which makes patients vulnerable to respiratory tract viral infections. The programme was out-licensed to AstraZeneca by Synairgen in June 2014 in a global deal worth up to $232 million plus tiered royalties. AstraZeneca is responsible for all development, regulatory and commercial activities and on-going costs associated with this programme. The licence agreement with AstraZeneca also provides the opportunity to expand the clinical programme into other pulmonary diseases, including COPD. This placebo-controlled Phase IIa trial seeks to enroll 220 asthma patients from countries in both the Northern and Southern Hemispheres (to maximize the benefit of access to a 'continuous' cold season). The study population will be GINA Step 4/5 asthma patients (that is patients requiring treatment with medium-to-high dose inhaled corticosteroids and a second controller medication) who have a history of severe exacerbations caused by cold viruses. The primary endpoint for the trial is the number of severe exacerbations during the 14 day dosing period.

AstraZeneca Enters into Agreement with Tillotts Pharma AG for Divestment of Global Rights, Outside the US, to Entocort

AstraZeneca announced that it has entered into an agreement with Tillotts Pharma AG for the divestment of global rights, outside the US, to Entocort (budesonide), a gastroenterology medicine for patients with mild to moderate Crohns disease and ulcerative colitis. Under the terms of the agreement, Tillotts will pay AstraZeneca a $215 million upon completion of the transaction to acquire the rights to sell and develop Entocort capsules and enema formulations outside the US. The transaction does not include the transfer of any AstraZeneca employees or facilities.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZN:LN 4,184.50 GBp -6.00

AZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $148.71 USD -0.62
Abbott Laboratories $50.69 USD -0.36
BASF SE €77.68 EUR +0.88
Eli Lilly & Co $84.15 USD -0.57
Valeant Pharmaceuticals International Inc C$337.49 CAD +10.79
View Industry Companies
 

Industry Analysis

AZN

Industry Average

Valuation AZN Industry Range
Price/Earnings 65.3x
Price/Sales 3.2x
Price/Book 4.9x
Price/Cash Flow 65.2x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.